- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Patent holdings for IPC class C07D 413/12
Total number of patents in this class: 7593
10-year publication summary
583
|
529
|
543
|
535
|
527
|
581
|
498
|
478
|
496
|
120
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Bristol-myers Squibb Company | 5080 |
183 |
F. Hoffmann-La Roche AG | 7958 |
181 |
Boehringer Ingelheim International GmbH | 4629 |
149 |
Novartis AG | 11238 |
147 |
AstraZeneca AB | 3042 |
120 |
Syngenta Participations AG | 4970 |
101 |
Hoffmann-La Roche Inc. | 3060 |
91 |
Merck Sharp & Dohme LLC | 3689 |
90 |
Takeda Pharmaceutical Company Limited | 2961 |
87 |
Rigel Pharmaceuticals, Inc. | 613 |
86 |
Epizyme, Inc. | 383 |
80 |
Gilead Sciences, Inc. | 1879 |
77 |
Bayer Cropscience AG | 2241 |
76 |
Amgen Inc. | 3779 |
76 |
Janssen Pharmaceutica N.V. | 3839 |
74 |
Bayer AG | 3045 |
69 |
BASF SE | 19740 |
68 |
Merck Patent GmbH | 5909 |
65 |
Shionogi & Co., Ltd. | 914 |
65 |
Vertex Pharmaceuticals Incorporated | 1581 |
64 |
Other owners | 5644 |